References
- Rosser T, Panigrahy A, McClintock W. The diverse clinical manifestations of tuberous sclerosis complex: a review. Sem Pediatr Neurol 2006;13:27-36
- Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008;372:657-68
- (NINDS) NIoNDaS. Tuberous Sclerosis Fact Sheet. Available at http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm. Accessed June 2015.
- Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron. Exp Nephrol 2011;118:e15-20
- Martignoni G, Pea M, Rocca PC, et al. Renal pathology in the tuberous sclerosis complex. Pathology 2003;35:505-12
- Rakowski SK, Winterkorn EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 2006;70:1777-82
- Cook JA, Oliver K, Mueller RF, et al. A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 1996;33:480-4
- O'Callaghan FJ, Noakes MJ, Martyn CN, et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 2004;94:853-7
- Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-24
- Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl J Med 2008;358:140-51
- Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. New Engl J Med 2006;355:1345-56
- Rouviere O, Nivet H, Grenier N, et al. Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn Intervent Imag 2013;94:225-37
- Harabayashi T, Shinohara N, Katano H, et al. Management of renal angiomyolipomas associated with tuberous sclerosis complex. J Urol 2004;171:102-5
- Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49:255-65.
- Mourikis D, Chatziioannou A, Antoniou A, et al. Selective arterial embolization in the management of symptomatic renal angiomyolipomas. Eur J Radiol 1999;32:153-9
- Allen LA, Smoyer Tomic KE, Wilson KL, et al. The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type. J Med Econ 2013;16:43-54
- Carls GS, Roebuck MC, Brennan TA, et al. Impact of medication adherence on absenteeism and short-term disability for five chronic diseases. J Occupat Environ Med Am Coll Occupat Environl Med 2012;54:792-805
- Epstein AJ, Groeneveld PW, Harhay MO, et al. Impact of minimally invasive surgery on medical spending and employee absenteeism. JAMA Surg 2013;148:641-7
- Ye X, Qian C, Liu J, et al. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI. Pharmacotherapy 2013;33:1062-70
- Allen LA, Smoyer Tomic KE, Smith DM, et al. Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure. Circulation. Heart Fail 2012;5:672-9
- Jha AK, Orav EJ, Epstein AM. Low-quality, high-cost hospitals, mainly in South, care for sharply higher shares of elderly black, Hispanic, and medicaid patients. Health Affairs 2011;30:1904-11
- Schneider G, Juday T, Wentworth C, III et al. Impact of health care payer type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA. AIDS Care 2013;25:1470-6